MarketingRx roundup: AbbVie debuts Vraylar campaign for depression; Amylyx re-ups “Get Inked” for ALS effort
In December, AbbVie received a fourth indication for Vraylar as an add-on to antidepressants for the treatment of major depressive disorder – and now it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
